High prevalence of SARS-CoV-2 antibodies and low prevalence of SARS-CoV-2 RNA in cats recently exposed to human cases

• Published in: BMC veterinary research Vol. 20; no. 1; pp. 304 - 12
• Main Authors: Daigle, Laurence, Khalid, Hattaw, Gagnon, Carl A, Arsenault, Julie, Bienzle, Dorothee, Bisson, Sarah-Kim, Blais, Marie-Claude, Denis-Robichaud, José, Forest, Caroline, Grenier St-Sauveur, Valérie, Koszegi, Marika, MacNicol, Jennifer, Nantel-Fortier, Nicolas, Nury, Charlotte, Prystajecky, Natalie, Fraser, Erin, Carabin, Hélène, Aenishaenslin, Cécile
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 09.07.2024; BioMed Central; BMC
• Subjects: Animals; Antibodies; Antibodies, Viral - blood; Automation; Bayesian analysis; Cat Diseases - epidemiology; Cat Diseases - virology; Cats; Coronaviruses; COVID-19; COVID-19 - diagnosis; COVID-19 - epidemiology; COVID-19 - veterinary; COVID-19 - virology; Cross-Sectional Studies; Disease transmission; Diseases; Enzyme-linked immunosorbent assay; Exposure; Female; Genetic aspects; Genomes; Growth; Households; Humans; Immunoglobulin G; Laboratories; Male; Mathematical models; Medical research; One Health; Prevalence; Prevention; Public health; Questionnaires; Rectum; Ribonucleic acid; Risk factors; RNA; RNA viruses; RNA, Viral; SARS-CoV-2; SARS-CoV-2 - immunology; Severe acute respiratory syndrome coronavirus 2; Testing; Viral antibodies; Canada; British Columbia Canada; COVID-19; Cats; SARS-CoV-2; Prevalence; Households; Exposure; One Health
• ISSN: 1746-6148; 1746-6148
• DOI: 10.1186/s12917-024-04150-4

The primary objective of this cross-sectional study, conducted in Québec and Bristish Columbia (Canada) between February 2021 and January 2022, was to measure the prevalence of viral RNA in oronasal and rectal swabs and serum antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) amongst cats living in households with at least one confirmed human case. Secondary objectives included a description of potential risk factors for the presence of SARS-CoV-2 antibodies and an estimation of the association between the presence of viral RNA in swabs as well as SARS-CoV-2 antibodies and clinical signs. Oronasal and rectal swabs and sera were collected from 55 cats from 40 households at most 15 days after a human case confirmation, and at up to two follow-up visits. A RT-qPCR assay and an ELISA were used to detect SARS-CoV-2 RNA in swabs and serum SARS-CoV-2 IgG antibodies, respectively. Prevalence and 95% Bayesian credibility intervals (BCI) were calculated, and associations were evaluated using prevalence ratio and 95% BCI obtained from Bayesian mixed log-binomial models. Nine (0.16; 95% BCI = 0.08-0.28) and 38 (0.69; 95% BCI = 0.56-0.80) cats had at least one positive RT-qPCR and at least one positive serological test result, respectively. No risk factor was associated with the prevalence of SARS-CoV-2 serum antibodies. The prevalence of clinical signs suggestive of COVID-19 in cats, mainly sneezing, was 2.12 (95% BCI = 1.03-3.98) times higher amongst cats with detectable viral RNA compared to those without. We showed that cats develop antibodies to SARS-CoV-2 when exposed to recent human cases, but detection of viral RNA on swabs is rare, even when sampling occurs soon after confirmation of a human case. Moreover, cats with detectable levels of virus showed clinical signs more often than cats without signs, which can be useful for the management of such cases.